Venus Remedies Reports Stellar Q1 Performance with 8-Fold Surge in Net Profit Aug 01, 2025
More news about Venus Remedies
27May 25
Venus Remedies Doubles Q4 Net Profit, Revenue Holds Steady
Venus Remedies reported a 100% increase in Q4 consolidated net profit, reaching ₹210.00 million, up from ₹105.00 million year-over-year. Revenue remained stable at ₹1.95 billion. The profit also improved quarter-over-quarter from ₹196.00 million. This significant profit growth without revenue increase suggests improved operational efficiency or successful cost-cutting measures.
26May 25
Venus Remedies Reports Strong Q4 Performance with Doubled Net Profit
Venus Remedies announced impressive Q4 results with net profit doubling to ₹210.00 crore, a 100% year-over-year increase. EBITDA rose by 48.79% to ₹290.00 crore, with the EBITDA margin improving to 14.87%. Revenue remained stable at ₹195.00 crore. For the full financial year, the company reported an 8.34% increase in revenue to ₹613.00 crore and a 7.14% rise in net profit to ₹28.50 crore.
22May 25
Venus Remedies Bolsters Global Presence with Ukrainian GMP Certification Renewal
Venus Remedies has successfully renewed its Good Manufacturing Practice (GMP) certification from Ukraine, ensuring continued operations and expansion in the Ukrainian market. This renewal validates the company's high-quality manufacturing standards, compliance with Ukrainian regulations, and facilitates ongoing access to the country's pharmaceutical market. The certification is strategically important for Venus Remedies, allowing market continuity, quality assurance, and a competitive edge in Ukraine. This development aligns with the company's global expansion strategy and commitment to international quality standards.
Venus Remedies Limited's investigational product VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the US FDA for treating bloodstream infections. VRP-034 is a novel supramolecular cationic formulation of polymyxin B sulphate designed to reduce nephrotoxicity while maintaining efficacy. The QIDP status offers benefits like priority review, fast track eligibility, and extended market exclusivity. Preclinical studies show up to 70% reduction in nephrotoxicity compared to existing polymyxin B treatments, with robust efficacy against resistant pathogens.
25Feb 25
Venus Remedies Secures Exclusive Rights for MET-X: A Potential Game-Changer in Fighting Antibiotic Resistance
Venus Remedies Limited has entered an exclusive license agreement with UK-based Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, in India. MET-X, designed to combat drug-resistant Gram-negative bacteria, will be initially combined with meropenem. The company plans to conduct Phase I trials in India, followed by Phase II/III trials for complicated urinary tract infections. This agreement addresses a critical need in India, where meropenem resistance is high and no approved MBL inhibitors exist. The development will adhere to international standards, potentially supporting global commercialization efforts.